A Phase 2 interventional study of SSGJ-707 and carboplatin in Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-21.
Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 170 studies in Endometrial Neoplasms with a site in China — 98 open to participants now, 120 under way, 21 of them phase 3. Endometrial Neoplasms · China.
Among the 170 studies in Endometrial Neoplasms with a site in China, this one is the 90th largest by planned enrollment of the 140 interventional ones that give a count, is one of 28 that started in 2024, is one of 41 in phase 2, reaches primary completion later than 17 of the 119 other live ones, and was the 110th registered.
1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.
Browse Endometrial Neoplasms studies →98 of the 170 studies in Endometrial Neoplasms with a site in China are open now. Recruiting first, the newest first:
Shanghai Huaota Biopharmaceutical Co., Ltd. · Sites in China
Ages 18+ · Women only
Pfizer · Sites in China, United States, Australia and 2 more countries
Ages 18+ · Women only
Catherin Zhang · Sites in China
Ages 18–75 · Women only
Guizhou Provincial People's Hospital · Sites in China
Ages up to 18 · Women only · Healthy volunteers
TJ Biopharma Co., Ltd. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
170 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 69 · Phase 3 29
First in 2000; this study’s year is marked. 28 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 115 across the 140 interventional studies, 840 across the 30 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 170 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., one of the names counted as 3SBio Inc.. Under that name alone:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is the lead sponsor of 59 studies on the registry; 22 are open to participants now.
3SBio Inc. has 1 study filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
34 of the studies in Endometrial Neoplasms with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04634877Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | 2026-11-20 |
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT07860203Catherin ZhangStellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery | 2026-12 |
| NCT051129913D Medicines (Sichuan) Co., Ltd.Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 170 studies in Endometrial Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SSGJ-707 · Drug: carboplatin · Drug: paclitaxel
Drug: SSGJ-707 · Drug: carboplatin · Drug: paclitaxel
Drug: SSGJ-707 · Drug: carboplatin · Drug: paclitaxel
Drug: SSGJ-707 · Drug: paclitaxel
SSGJ-707 is a bispecific antibody against human PD-1 and VEGF
chemotherapy
chemotherapy
ORR
Objective response rate
Time frame: 12 months
Safety and tolerability
Safety and tolerability assessed by incidence and severity of adverse events
Time frame: 12 months
PFS
The efficacy end point
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Aug 2025, 10 months after the start.
Of 139 phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 115. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. →